Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Samrat Pharmachem's Revenue for the
three
months ended in Jun. 2026 was ₹798 Mil. Samrat Pharmachem's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹510 Mil.
Hence, Samrat Pharmachem's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.56.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Samrat Pharmachem Receivables Turnover Related Terms
Samrat Pharmachem Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Samrat Pharmachem's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530125 vs DOW: Receivables Turnover Comparison
For the Chemicals subindustry, Samrat Pharmachem's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Samrat Pharmachem Receivables Turnover vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Samrat Pharmachem's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Samrat Pharmachem's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Samrat Pharmachem (BOM:530125) has a Receivables Turnover of 1.56 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Samrat Pharmachem and its competitors. According to the industry distribution chart, Samrat Pharmachem ranks #836 out of 1585 companies in the Chemicals industry, placing it in the top 52.7%.
Is Samrat Pharmachem's Receivables Turnover too high?
Samrat Pharmachem's current Receivables Turnover is 1.56. The Chemicals industry median Receivables Turnover is 5.76. Samrat Pharmachem's value of 1.56 is 72.9% below this industry median. Based on the distribution chart, Samrat Pharmachem ranks #836 out of 1585 companies in the Chemicals industry, which is below the industry midpoint. Overall, Samrat Pharmachem has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Samrat Pharmachem's Receivables Turnover compare to DOW?
According to the Chemicals industry distribution chart, Samrat Pharmachem ranks #836 out of 1585 companies for Receivables Turnover. This places Samrat Pharmachem in the lower half of its industry. The industry median Receivables Turnover is 5.76. Samrat Pharmachem's value of 1.56 is 72.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Chemicals company?
The median Receivables Turnover among Chemicals companies is 5.76, based on 1,585 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Samrat Pharmachem's current Receivables Turnover of 1.56 is 72.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Samrat Pharmachem and its competitors. For the Chemicals industry, the median Receivables Turnover is 5.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Samrat Pharmachem's current Receivables Turnover is 1.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samrat Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Samrat Pharmachem (BOM:530125) is currently considered Possible Value Trap. The stock's GF Value™ is ₹355.67, compared to a current price of ₹229.90 — trading 35.4% below its estimated fair value. The current Receivables Turnover is 1.56 and 72.9% below the Chemicals industry median of 5.76. Samrat Pharmachem's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Samrat Pharmachem (BOM:530125), the current Receivables Turnover is 1.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Samrat Pharmachem (BOM:530125) Overvalued in 2026?
Based on GuruFocus' analysis, Samrat Pharmachem stock appears to be undervalued.
The current stock price of ₹229.90 is trading 35.4% below its estimated GF Value™ of ₹355.67.
GuruFocus considers Samrat Pharmachem to be Possible Value Trap.
Key valuation signals for BOM:530125:
Receivables Turnover: 1.56
GF Value™: ₹355.67 vs. price of ₹229.90 (35.4% below fair value)
Industry Position: 72.9% below the Chemicals median (#836 of 1585)
No single metric tells the full story. See the BOM:530125 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
69GF Score
Get the complete analysis for BOM:530125
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530125 has been successfully added to your 
